NeurAxis (NRXS) Q4 2025 earnings review
The Foundational Grind is Over; The Execution Phase Begins
NeurAxis successfully bridged the gap to its massive January 1, 2026 catalyst. Q4 2025 revenue hit a record $968K (+27% YoY), marking the sixth straight quarter of double-digit growth. However, the reported quarter is just the prelude. The real story is management's real-time Q1 commentary: the Category I CPT code activation and 100M+ covered lives have triggered a 10x surge in prior authorization submissions. The primary risk has officially shifted from reimbursement mechanics to hospital execution. With $6M+ in post-raise liquidity, NeurAxis has the runway to staff its commercial footprint and convert this pent-up demand into high-margin revenue.
🐂 Bull Case
The billing code activated on January 1, 2026, instantly removing the largest barrier to physician adoption. Real-time Q1 data shows a massive acceleration in patient submissions.
Gross margin ticked up sequentially to 85.4% in Q4. Management confirmed the mix is shifting away from heavily discounted financial assistance programs toward full insurance reimbursement.
🐻 Bear Case
The surge in demand is overwhelming unprepared clinics. A key hospital is already booked out to September because they lack dedicated IB-Stim clinic time, stalling near-term revenue realization.
Payers have balked at covering the adult indication without an adult-specific RCT. This relegates the massive adult functional dyspepsia market to cash-pay only in the near term.
⚖️ Verdict: 🟢
Bullish. The existential regulatory and reimbursement hurdles that historically suppressed NeurAxis's growth are officially cleared. While hospital capacity constraints are frustrating, they are a byproduct of overwhelming demand rather than a lack of it.
Key Themes
Category I CPT Code Triggers Submission Surge
Accelerating. The Jan 1, 2026 activation of the permanent billing code fundamentally changes the company's trajectory. Management reported a 10x increase in prior authorization submissions in early Q1 compared to 2025. This code not only streamlines billing but provides physicians with crucial RVU (Relative Value Unit) compensation, financially incentivizing them to adopt the therapy.
Payer Coverage Hits Critical Mass
Accelerating. NeurAxis added a massive 45 million covered lives in late December via a major national health insurer, bringing the total to over 100 million. This effectively transforms the company's sales mix. As more patients transition from the heavily discounted Patient Assistance Program (historically a ~65% discount) to full-reimbursement purchase orders, average selling prices and top-line revenue will compound.
VA Rollout Beating Expectations
Accelerating. The recently awarded Federal Supply Schedule (FSS) contract is already bearing fruit. Despite management's initial assumption that the bureaucratic VA system would yield no Q1 orders, multiple facilities have already placed initial orders and reorders. With 7 million active VA patients and an estimated 3% functional dyspepsia prevalence, this provides a highly scalable federal pipeline.
Medical Policy Remains the Gatekeeper (Macro)
Stable. Management clarified a critical macro reality: payers will not blindly reimburse based solely on the new CPT code. Written medical policy coverage remains essential. Hospitals with only 20-25% of their patient base covered by approved payers are hesitant to roll out the therapy broadly due to perceived health equity issues. Securing the remaining large payers is mandatory to unlock full clinical adoption.
Hospital Workflow is the New Bottleneck
Stable. The execution risk has moved from the payer's desk to the hospital's scheduling software. NeurAxis noted that some hospitals are already booking IB-Stim treatments out to September because they only allocate brief windows for the procedure. Expanding "IB-Stim clinic time" requires navigating sluggish hospital committees, meaning revenue realization will lag behind the spike in prior authorization submissions.
RED Device Contradicts the Margin Recovery Narrative
Reversing. While the positive narrative focuses on full-reimbursement driving up margins, the Q4 gross margin actually fell 100 bps YoY to 85.4%. A specific culprit: the RED device. Despite being touted as a new growth vector with an existing CPT code, RED sales carry a substantially lower gross margin than IB-Stim, and slow adoption forced the company to take obsolescence charges on expired RED inventory.
Adult Indication Demands an RCT
Stable. The FDA cleared IB-Stim for adults based on extrapolated pediatric data, but payers are not biting. NeurAxis conceded that broad medical policy coverage for adults will require a large randomized controlled trial. They have initiated this trial at the Cleveland Clinic, effectively pausing broad adult commercialization (outside the VA and cash-pay) for the next ~18 months.
Other KPIs
Accelerating. Total OpEx increased 20% YoY. The company is actively front-loading expenses to capitalize on the 2026 catalysts, noting higher sales commissions tied to volume and targeted marketing costs ahead of the January CPT code launch. Management reclassified some G&A to Selling and R&D to better reflect the commercial push.
Stable. The company ended 2025 with $5.0 million in cash and subsequently raised $2.6 million via ATM and warrants in early 2026. Against a historical core cash burn of ~$1.5 million per quarter, the balance sheet provides ample runway to fund the aggressive commercial scale-up without an immediate need for dilutive financing.
Guidance
Accelerating. Management explicitly refused to give quantitative guidance until the Q1 earnings call, but cited "surprisingly better than expected" early Q1 revenue. The primary driver is the shift from discounted units to full-reimbursement units across 100M+ covered lives.
Accelerating. After dipping in FY25 due to Patient Assistance Program discounting and RED inventory write-offs, the CFO explicitly stated they expect to "reverse that trend in 2026" as the new Cat I CPT code unlocks full insurance payments.
Accelerating. Management expects significant operating expense leverage. While raw dollars spent on Selling and R&D will increase to support the commercial rollout and adult RCT, revenue growth is projected to drastically outpace these additions, narrowing the operating loss.
Key Questions
Prior Authorization Conversion Rates
You noted a 10x surge in prior authorization submissions in Q1. Given that some accounts only have partial payer coverage, what percentage of these submissions are actually converting into approvals and scheduled treatments?
Hospital Capacity Timelines
With clinics booking out to September due to a lack of dedicated IB-Stim time, what is the average cycle time for a children's hospital committee to approve and allocate new operational bandwidth for this procedure?
RED Device Commercial Strategy
The RED device caused a margin drag and inventory obsolescence charges this quarter. Is the company reconsidering the resource allocation for RED, or do you expect the margin profile to improve as adoption scales?